These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Hussein AA; Al-Zaben A; Ghatasheh L; Natsheh A; Hammada T; Abdel-Rahman F; Abu-Jazar H; Sharma S; Najjar R; Frangoul H Pediatr Blood Cancer; 2013 Aug; 60(8):1345-9. PubMed ID: 23424175 [TBL] [Abstract][Full Text] [Related]
3. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India. Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007 [TBL] [Abstract][Full Text] [Related]
4. HLA-matched sibling stem cell transplantation in children with β-thalassemia with anti-thymocyte globulin as part of the preparative regimen: the Greek experience. Goussetis E; Peristeri I; Kitra V; Vessalas G; Paisiou A; Theodosaki M; Petrakou E; Dimopoulou MN; Graphakos S Bone Marrow Transplant; 2012 Aug; 47(8):1061-6. PubMed ID: 22080966 [TBL] [Abstract][Full Text] [Related]
5. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896 [TBL] [Abstract][Full Text] [Related]
6. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran. Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency. Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864 [TBL] [Abstract][Full Text] [Related]
8. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia. Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217 [TBL] [Abstract][Full Text] [Related]
9. Unrelated Donor Peripheral Blood Stem Cell Transplantation for Patients with β-Thalassemia Major Based on a Novel Conditioning Regimen. Sun L; Wang N; Chen Y; Tang L; Xing C; Lu N; Shi Y; Ma Y; Lin F; Yu K; Feng J Biol Blood Marrow Transplant; 2019 Aug; 25(8):1592-1596. PubMed ID: 30951841 [TBL] [Abstract][Full Text] [Related]
10. Results of hematopoietic stem cell transplant in Shiraz: 15 years experience in southern Iran. Ramzi M; Nourani H; Zakerinia M; Dehghani M; Vojdani R; Haghshenas M Exp Clin Transplant; 2010 Mar; 8(1):61-5. PubMed ID: 20199373 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience. Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193 [TBL] [Abstract][Full Text] [Related]
12. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813 [TBL] [Abstract][Full Text] [Related]
13. [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia]. Nakamae H; Terada Y; Nakane T; Koh H; Nakamae M; Aimoto R; Hirose A; Hayashi Y; Nishimoto M; Inoue E; Yoshimura T; Inoue A; Koh KR; Yamane T; Hino M Gan To Kagaku Ryoho; 2010 Sep; 37(9):1691-5. PubMed ID: 20841930 [TBL] [Abstract][Full Text] [Related]
14. Hematopoietic stem cell transplantation for beta-thalassemia major: experience in south of Iran. Ramzi M; Nourani H; Zakernia M; Hamidian Jahromi AR Transplant Proc; 2004 Oct; 36(8):2509-10. PubMed ID: 15561298 [TBL] [Abstract][Full Text] [Related]
15. Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen. Korula A; Pn N; Devasia A; Lakshmi KM; Abraham A; Sindhuvi E; George B; Srivastava A; Mathews V Biol Blood Marrow Transplant; 2018 Jan; 24(1):103-108. PubMed ID: 29032269 [TBL] [Abstract][Full Text] [Related]
16. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. Caocci G; Orofino MG; Vacca A; Piroddi A; Piras E; Addari MC; Caria R; Pilia MP; Origa R; Moi P; La Nasa G Am J Hematol; 2017 Dec; 92(12):1303-1310. PubMed ID: 28850704 [TBL] [Abstract][Full Text] [Related]
17. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
18. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838 [TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis. Schetelig J; Bornhäuser M; Kiehl M; Schwerdtfeger R; Kröger N; Runde V; Zabelina T; Held TK; Thiede C; Fauser AA; Beelen D; Zander A; Ehninger G; Siegert W; Bone Marrow Transplant; 2004 Mar; 33(5):483-90. PubMed ID: 14716342 [TBL] [Abstract][Full Text] [Related]
20. [Haploidentical hematopoietic stem cell transplantation for beta-thalassemia major in children]. Hao WG; Sun X; Liu S; Zhao Z; Chen ZX Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jul; 11(7):546-8. PubMed ID: 19650987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]